Historical Valuation
Bicycle Therapeutics PLC (BCYC) is now in the Undervalued zone, suggesting that its current forward PS ratio of 16.73 is considered Undervalued compared with the five-year average of -6.71. The fair price of Bicycle Therapeutics PLC (BCYC) is between 7.02 to 23.17 according to relative valuation methord. Compared to the current price of 6.63 USD , Bicycle Therapeutics PLC is Undervalued By 5.62%.
Relative Value
Fair Zone
7.02-23.17
Current Price：6.63
5.62%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Bicycle Therapeutics PLC (BCYC) has a current Price-to-Book (P/B) ratio of 0.75. Compared to its 3-year average P/B ratio of 1.86 , the current P/B ratio is approximately -59.80% higher. Relative to its 5-year average P/B ratio of 2.91, the current P/B ratio is about -74.27% higher. Bicycle Therapeutics PLC (BCYC) has a Forward Free Cash Flow (FCF) yield of approximately -52.20%. Compared to its 3-year average FCF yield of -18.93%, the current FCF yield is approximately 175.80% lower. Relative to its 5-year average FCF yield of -13.59% , the current FCF yield is about 284.06% lower.
P/B
Median3y
1.86
Median5y
2.91
FCF Yield
Median3y
-18.93
Median5y
-13.59
Competitors Valuation Multiple
AI Analysis for BCYC
The average P/S ratio for BCYC competitors is 19.55, providing a benchmark for relative valuation. Bicycle Therapeutics PLC Corp (BCYC.O) exhibits a P/S ratio of 16.73, which is -14.43% above the industry average. Given its robust revenue growth of 338.49%, this premium appears sustainable.
Performance Decomposition
AI Analysis for BCYC
1Y
3Y
5Y
Market capitalization of BCYC increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of BCYC in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is BCYC currently overvalued or undervalued?
Bicycle Therapeutics PLC (BCYC) is now in the Undervalued zone, suggesting that its current forward PS ratio of 16.73 is considered Undervalued compared with the five-year average of -6.71. The fair price of Bicycle Therapeutics PLC (BCYC) is between 7.02 to 23.17 according to relative valuation methord. Compared to the current price of 6.63 USD , Bicycle Therapeutics PLC is Undervalued By 5.62% .
What is Bicycle Therapeutics PLC (BCYC) fair value?
BCYC's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Bicycle Therapeutics PLC (BCYC) is between 7.02 to 23.17 according to relative valuation methord.
How does BCYC's valuation metrics compare to the industry average?
The average P/S ratio for BCYC's competitors is 19.55, providing a benchmark for relative valuation. Bicycle Therapeutics PLC Corp (BCYC) exhibits a P/S ratio of 16.73, which is -14.43% above the industry average. Given its robust revenue growth of 338.49%, this premium appears sustainable.
What is the current P/B ratio for Bicycle Therapeutics PLC (BCYC) as of Jan 09 2026?
As of Jan 09 2026, Bicycle Therapeutics PLC (BCYC) has a P/B ratio of 0.75. This indicates that the market values BCYC at 0.75 times its book value.
What is the current FCF Yield for Bicycle Therapeutics PLC (BCYC) as of Jan 09 2026?
As of Jan 09 2026, Bicycle Therapeutics PLC (BCYC) has a FCF Yield of -52.20%. This means that for every dollar of Bicycle Therapeutics PLC’s market capitalization, the company generates -52.20 cents in free cash flow.
What is the current Forward P/E ratio for Bicycle Therapeutics PLC (BCYC) as of Jan 09 2026?
As of Jan 09 2026, Bicycle Therapeutics PLC (BCYC) has a Forward P/E ratio of -1.94. This means the market is willing to pay $-1.94 for every dollar of Bicycle Therapeutics PLC’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Bicycle Therapeutics PLC (BCYC) as of Jan 09 2026?
As of Jan 09 2026, Bicycle Therapeutics PLC (BCYC) has a Forward P/S ratio of 16.73. This means the market is valuing BCYC at $16.73 for every dollar of expected revenue over the next 12 months.